Incyte and Genesis Therapeutics Forge Strategic Collaboration to Accelerate Small Molecule Drug Discovery Using AI

Incyte  and Genesis Therapeutics, Inc. announced  that the companies have entered into a strategic collaboration focused on the researc...

February 21, 2025 | Friday | News
European Commission Grants Conditional Marketing Authorization for Gilead’s Seladelpar in Primary Biliary Cholangitis

Gilead Sciences, Inc. announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of prima...

February 21, 2025 | Friday | News
Bristol Myers Squibb Announces Positive Final Overall Survival Data for Opdivo® in Resectable NSCLC

Bristol Myers Squibb announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which evaluated Opdivo (ni...

February 21, 2025 | Friday | News
GSK Announces China’s Acceptance of New Drug Application for Nucala (Mepolizumab) as COPD Treatment

GSK plc announced that the China National Medical Products Administration has accepted for review the new drug application for the use of Nucala ...

February 21, 2025 | Friday | News
Genprex Advances Diabetes Program with Strategic Collaboration to Explore Non-Viral Gene Therapy Delivery System

Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced the adv...

February 20, 2025 | Thursday | News
Phanes Therapeutics Doses First Patient in Clinical Trial of Peluntamig (PT217) for Advanced Cancers

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced that the f...

February 20, 2025 | Thursday | News
Spinal Cord Injury (SCI) Cases Expected to Rise by 2034, Highlighting the Need for Improved Treatments and Support

Spinal cord injury (SCI) is a sudden disruption of the spinal cord's neural tissue within the spinal canal, caused by trauma, disease, or degeneration. Thi...

February 20, 2025 | Thursday | News
Nona Biosciences Partners with UAB to Advance B Cell Development Research through Innovative Licensing Agreement

Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to I™),  announced a licensing agreement with ...

February 20, 2025 | Thursday | News
Ultragenyx Announces FDA Acceptance of BLA for UX111 Gene Therapy to Treat Sanfilippo Syndrome Type A

Ultragenyx Pharmaceutical Inc. announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted for review the Biologics License Applicatio...

February 19, 2025 | Wednesday | News
Grifols Completes Recruitment for Phase 1/2 Study of Subcutaneous Alpha1-Proteinase Inhibitor for AAT Deficiency

Grifols , a global healthcare company and leading manufacturer of plasma-derived medicines,  announced it has finished recruiting the second cohort of...

February 19, 2025 | Wednesday | News
Gilead Sciences Announces FDA Acceptance of NDA for Lenacapavir as Twice-Yearly HIV Prevention Treatment

Gilead Sciences, Inc.  announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapa...

February 19, 2025 | Wednesday | News
Biogen and Stoke Therapeutics Collaborate on Zorevunersen for Dravet Syndrome Treatment

Biogen Inc.  and Stoke Therapeutics, Inc. announced a collaboration for the development and commercialization of zorevunersen, a potential f...

February 19, 2025 | Wednesday | News
Sanofi and Regeneron’s Dupixent Gains FDA Priority Review for Bullous Pemphigoid Treatment

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) t...

February 19, 2025 | Wednesday | News
European Commission Grants Conditional Approval for Merck’s WELIREG® (belzutifan) to Treat VHL Disease-Associated Tumors and Advanced RCC

 Merck known as MSD outside of the United States and Canada, announced that the European Commission (EC) has conditionally approved WELIREG® ...

February 19, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close